SHTDF — Sinopharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapSuper Stock

Annual income statement for Sinopharm Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	HKAS	HKAS	HKAS	HKAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	425,273	456,415	521,051	552,148	596,570
Cost of Revenue
Gross Profit	37,531	40,323	44,051	47,434	48,512
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	409,250	438,788	501,949	531,605	576,367
Operating Profit	16,023	17,626	19,103	20,543	20,203
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	13,760	15,598	17,003	18,564	19,512
Provision for Income Taxes
Net Income After Taxes	10,620	12,097	13,065	14,345	15,010
Minority Interest
Net Income Before Extraordinary Items
Net Income	6,253	7,187	7,759	8,526	9,054
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	6,251	7,187	7,759	8,526	9,054
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.13	2.33	2.62	2.74	2.79
Dividends per Share